The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of targeted therapies (TT) after HIF-2? inhibitor-based treatment in advanced renal cell carcinoma (aRCC).
 
Patricia Rioja
No Relationships to Disclose
 
Macarena Rey
No Relationships to Disclose
 
Jorge Esteban Villarrubia
Expert Testimony - Bristol-Myers Squibb; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Deciphera
 
David Plata
No Relationships to Disclose
 
Ileana Sparagna
No Relationships to Disclose
 
Fabio Schutz
Employment - Janssen medical Affairs (I); Sanofi (I)
Consulting or Advisory Role - Adium Pharma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Adium Pharma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer
Research Funding - BMS Brazil (Inst); Janssen Oncology (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Merck Sharp & Dohme; Roche
 
Ray Manneh
Leadership - Sociedad de Oncología y Hematología del Cesar (I)
Honoraria - Amgen; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; Tecnofarma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche; Sanofi; Tecnofarma
Speakers' Bureau - Asociación Colombiana de Hematoligía y Oncología (ACHO); San Jorge Foundation
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Merck Sharp & Dohme; Novartis; Pfizer
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme; Pfizer; Roche/Genentech
 
Roberto Iacovelli
Honoraria - Astellas Pharma; IPSEN; MSD; Pfizer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Eisai; Genenta Science; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi
Speakers' Bureau - Ipsen; Janssen; MSD; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen; MSD; Pfizer
 
Ronan Flippot
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Pfizer
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; Merck/Pfizer; Merck/Pfizer
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Guillermo de Velasco
Honoraria - Astellas Pharma; BMS; Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - BMS; BMS; Roche